ICPerMed featured and honoured in this session best practices in personalised medicine research through the ICPerMed Recognition 2020, that aims to recognise, encourage, promote and disseminate outstanding examples. The third ICPerMed Recognition edition was open to candidates worldwide, who have published scientific papers or developed best practice strategies in the field of personalised medicine between 1st January 2018 and 31st October 2019. The winners presented their results during this session.
Recognition 2020 - speakers
The following winners presented their results during a dedicated plenary session:
A pathology-supported genetic testing platform for application of breast cancer pharmacogenetics at the point of care (POC) using an integrated service and research approach
Department of Pathology, Stellenbosch University and National Health Laboratory Service - NHLS- Tygerberg Hospital, South Africa
A combined ANXA2-NDRG1-STAT1 gene signature predicts response to chemoradiotherapy in cervical cancer
Sacro Cuore Cattolica University, Italy
The Personalised Medicine Coalition: Developing Strategies for the Integration of Personalised Medicine in Health Care Practice
Science Policy at PMC, USA
International Tinnitus Research – Novel approaches in Personalised Medicine Research, Teaching and Treatment - The ESIT Project
The ESIT Consortium
Recognition 2020 - Posters
ICPerMed offered to the following authors a stage to present their work with a poster. Participants to the ICPerMed virtual conference had the possibility to consult the posters and asked for an individual presentation through a private visioconference tool all along the conference.
On behalf of the Board of the Austrian Platform for Personalized Medicine Medical University of Vienna, Austria
Connecting the Austrian PerMed Community: The Austrian Platform for Personalized Medicine
Dr. Philipp Hofer heads the tissue biobank of the Department of Pathology of the Medical University of Vienna. As biotechnologist by training, he earned his doctoral degree from the University of Natural Resources and Applied Life Sciences, Vienna.
(I) His diploma and PhD theses at the Institute of Cancer Research of the Medical University of Vienna were dedicated to the identification of biomarkers for various malignant diseases. During conduct of these large-scaled case-control studies in the field of preventive cancer research, utilizing thousands of fluid biobank samples, he recognized the critical importance of well-characterized collections of biospecimens and associated clinical data. In his current position, he has devoted himself to establish sustainable prospective research collections of quality-defined tissue samples in close collaboration with various clinical partners thereby aiming to contribute to an improved reproducibility of preclinical research.
(II) As coordinator and board member of the Austrian Platform for Personalized Medicine (ÖPPM, www.personalized-medicine.at/) Philipp has been engaged in the implementation and management of a nation-wide networking platform from the very start. The ÖPPM represents a non-profit organization that strives to interconnect all interested parties in the field, informs the Austrian public and fosters the intersectoral collaboration of different stakeholders.
University of Toronto & St. Michael’s Hospital, Canada
Health outcomes, utility and costs of returning incidental results from genomic sequencing in a Canadian cancer population: protocol for a mixed-methods randomized controlled trial
Dr. Bombard is a genomics health services researcher and Scientist at the Li Ka Shing Knowledge Institute of St. Michael’s Hospital. She is an Associate Professor at the University of Toronto in the Institute of Health Policy Management and Evaluation. Her research evaluates the adoption of new genomic technologies in clinical practice, including digital/virtual tools. She conducts public and patient engagement to advance health technology assessment and health service delivery. She advises numerous international policy initiatives; her research informs policy development in this area. Dr. Bombard was the inaugural recipient of the Maurice McGregor Award for Demonstrated Excellence and Leadership Potential from the Canadian Agency for Drugs and Technologies in Health (CADTH) and also received a ‘Rising Star’ award from CIHR’s Institute of Health Services and Policy Research. She has been awarded a CIHR Foundation grant as an Early Career Investigator, and a CIHR New Investigator Award. Dr. Bombard holds Fellowships from Yale University (in Health Policy), Memorial Sloan-Kettering Cancer Center (in Cancer Genomics) and the University of Toronto (in Health Services Research).
The Hebrew University of Jerusalem, Israel
Cell “Mechanomics” - a novel approach for cancer diagnosis and personalized therapy
Prof. Ofra Benny is the Head of the Lab for Nanomedicine and the Tumor Microenvironment at the Hebrew University of Jerusalem. Her Team focuses on nanomedicine, 3D printing and microfluidics for drug delivery and diagnostics in cancer. Prof. Benny is an Horizon2020 ERC starting grant awardee for her research in mechanical targeting of nanoparticles as an approach for personalized therapy in cancer. Her research lead to many patents as well as translation towards clinical usage. Her publications in the field of biomedicine include major journals such as Nature Biotechnology (journal cover), Science Advances, JCI, and more and her work was cited more than 1400 times. Before joining the Hebrew university Ofra was an Instructor at Harvard Medical School as well as a research associate at the Boston Children’s Hospital. She did her postdoctoral training at Harvard Medical School – Boston Children’s Hospital in Judah Folkman’s Lab.
Section for Translational Medical Ethics, National Center for Tumor Diseases, Heidelberg, Germany
EURAT (Ethical and Legal Aspects in Whole Genome Sequencing)
Rui Manuel Reis
Barretos Cancer Hospital, Brazil
Expression of GNAS, TP53, and PTEN Improves the Patient Prognostication in SHH Medulloblastoma
Vice-Dean of Master/PhD Program; Executive and Scientific Director of the Teaching and Research
Institute (IEP); Coordinator of the Molecular Oncology Research Center (CPOM); and Scientific Director of the Molecular Diagnostic Laboratory at Barretos Cancer Hospital, Barretos, SP. Brazil.
Invited Associate Professor at the University of Minho, School of Medicine (Braga, Portugal). Graduation in Biology at University of Porto (Portugal), PhD in neuro-oncology at IARC (Lyon, France) and Porto University, Post-doc fellowship in cancer genomics at Free University Medical Center (Amsterdam, Netherlands) and IPATIMUP (Porto, Portugal).
My expertise is in cancer biomarkers across distinct tumor types, and applying different methodologies, from gene mutations, copy number aberrations to gene expression alterations.
Experience in international collaborations, such as COST Action, Marie Curie Conferences, Steering
Committee of ICGC and WIN consortia. Author of more than 300 papers.